Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INTERLEUKIN 29 MUTANT PROTEIN
Document Type and Number:
WIPO Patent Application WO/2021/238302
Kind Code:
A1
Abstract:
Provided are an interleukin 29 (IL29) mutant protein, a fusion protein containing the mutant protein, a conjugate, a pharmaceutical composition, a product and a kit. The provided IL29 mutant protein has good activity and stability, and can effectively prevent and/or treat virus infectious diseases, tumors and other diseases needing to regulate the body immune function.

Inventors:
YANG LIU (CN)
LI YAN (CN)
FENG JING (CN)
GUO WANJUN (CN)
PAN HAI (CN)
Application Number:
PCT/CN2021/075907
Publication Date:
December 02, 2021
Filing Date:
February 08, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SCIWIND BIOSCIENCES CO LTD (CN)
International Classes:
C07K14/555; A61P31/12; A61P35/00; C07K1/107; C12N1/21; C12N15/20; C12N15/70
Domestic Patent References:
WO2011140086A22011-11-10
Foreign References:
CN109293782A2019-02-01
CN105085658A2015-11-25
CN107698682A2018-02-16
CN105085657A2015-11-25
CN103923209A2014-07-16
Other References:
LI, LIYUN ET AL.: "Site-directed Mutation on Lys43 of h IL-29 and Antineoplastic Analysis of the Variant", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 47, no. 3, 31 December 2016 (2016-12-31), pages 282 - 287, XP055871720
DUMOUTIER L, ET AL: "Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 31, 30 July 2004 (2004-07-30), US , pages 32269 - 32274, XP002321256, ISSN: 0021-9258, DOI: 10.1074/jbc.M404789200
See also references of EP 4159748A4
Attorney, Agent or Firm:
BEIJING CAIHE LAW FIRM (CN)
Download PDF: